PHARMOS CORP

PHARMOS CORP, operating in the Pharmaceutical Preparations sector tied to SIC 2834, crafts and markets specialty therapeutic compounds aimed at hospitals, clinics, and research facilities that demand tightly controlled formulations; its work centers on delivering advanced sterile injectables, oncology adjuncts, and bespoke biologic stabilizers that help address complex treatment regimens. As a smaller player without a listed ticker, the company still leans on nimble internal manufacturing, stringent quality systems, and partnerships with contract development organizations to reach institutional buyers who prioritize compliance and consistency. Regulatory oversight from the FDA and ongoing pressure to keep up with GMP, supply-chain transparency, and evolving labeling mandates represent material risks, along with the capital sensitivity of long R&D cycles and the need to maintain scale amidst larger competitors. Investors and analysts seeking the most recent disclosures can note the latest Form 10-Q dated November 1999 as a historical reference point; for live updates, view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025